Compare TONX & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TONX | IVVD |
|---|---|---|
| Founded | N/A | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.6M | 212.6M |
| IPO Year | 2013 | 2021 |
| Metric | TONX | IVVD |
|---|---|---|
| Price | $2.98 | $0.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 182.4K | ★ 4.6M |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 69.21 | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | $32,000.00 | ★ $53,426,000.00 |
| Revenue This Year | N/A | $12.40 |
| Revenue Next Year | N/A | $44.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 433.33 | 110.47 |
| 52 Week Low | $1.75 | $0.53 |
| 52 Week High | $4.44 | $3.07 |
| Indicator | TONX | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 44.30 | 37.35 |
| Support Level | $2.85 | $0.60 |
| Resistance Level | $3.58 | $1.02 |
| Average True Range (ATR) | 0.17 | 0.06 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 39.07 | 9.53 |
TON Strategy Co is a digital asset treasury and Web3 ecosystem company focused on supporting The Open Network, a public blockchain integrated with Telegram and designed for fast, scalable transactions and decentralized applications. Its core business is managing its holdings of Toncoin (TON), including staking tokens to support network validation and earn rewards, while adhering to regulatory, accounting, and risk management standards. The company also pursues Web3 initiatives to support the ecosystem's growth and adoption. It operates through MARKET. live, Go Fund Yourself, and TON segments, with MARKET.live generating maximum revenue as a multi-vendor livestream shopping platform that combines e-commerce and entertainment across social and video channels.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.